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esponses has stimulated new vaccine-concepts, especially
n the ﬁeld of adjuvant development.
Over the past two decades GSK Biologicals has developed
n Adjuvant Systems (AS) platform. AS families are formu-
ated with selected antigen(s) and are designed to enhance
he immune response to the targeted pathogen for the tar-
et population. Extensive preclinical and clinical testing
as lead to the development of AS-based candidate vac-
ines for malaria (RTS,S), HSV, H5N1 prepandemic inﬂuenza,
nd licensed vaccines for HBV and cervical cancer preven-
ion (HPV) formulated with novel adjuvant technology.The
SK proprietary novel Adjuvant System AS04 (aluminium
ydroxide combined with the immunostimulatory molecule,
-0-desacyl-4′-monophosphoryl lipid A) has been combined
ith HPV 16 and -18 virus-like-particles to tailor the immune
esponse optimally against a virus that typically hides from
he immune system.
The immune response induced by the AS04-adjuvanted
ervical cancer vaccine has been assessed in pre-clinical and
linical studies. In clinical studies, GSK’s both HPV-16 and -
8 L1-VLPs when adjuvanted with AS04, induced a stronger
nd more sustained immune response for at least 4 years
fter the ﬁrst dose, than when adjuvanted with aluminium
ydroxide alone. In addition, AS04 allowed for higher and
ustained concentrations of neutralising antibodies, as well
s higher frequencies of memory B-cells.1
New vaccine technologies have opened the door to vac-
ination against diseases that were not preventable before.
SK has formulated its cervical cancer vaccine with AS04 to
ddress the need for long term protection against oncogenic
PV, a virus that typically hides from the immune system and
or which the disease remain silent for years, if not detected
y classical screening methods such as PAP smears.
eference
1. Giannini SL, et al. Vaccine 2006;24:5937—49.
oi:10.1016/j.ijid.2008.05.103
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mplementation of Cervical Cancer Vaccination. Reaching
irls and Women: Challenges and Opportunities
-K. Tay
Singapore General Hospital, Singapore, Singapore
ervical cancer is the most common cancer in women in
any parts of Asia. Indeed, 54% of the world’s cervical can-
er burden is in Asia. Although cervical cancer screening
ith Pap smears has been effective, most Asian countries
on’t have the resources to implement a comprehensive
creening programme. Implementation of vaccination pro-
ides a realistic approach to improve cervical cancer control
n these countries.
In Asia, successful implementation of cervical cancer vac-
ination can present more of a challenge than it does on
ther continents. Experience following the introduction of
accination against common childhood infections highlights
everal practical issues, particularly concerning vaccination
olicy, ﬁnancing and system capacity for vaccine delivery
p
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nd inoculation. While the efﬁcacy and tolerability of anti-
PV-16/18 vaccines are well established, policymakers in
any Asian countries aren’t ready to formulate a national
olicy.
Implementation of anti-HPV-16/18 vaccination in Asia
s likely to start with opportunistic vaccination of individ-
al women. Physicians will introduce the vaccine to their
atients seeking cervical screening or attending consulta-
ions for other reasons. Caretakers will also discuss the
eneﬁts of vaccination for their adolescent daughters with
hese patients. In some Asian regions, opportunistic cytol-
gy screening has reached a high level of penetration and
ervical cancer incidence is declining. Opportunistic anti-
PV-16/18 vaccination may gain momentum in a similar
anner to cytology screening. Once sufﬁcient demand from
ndividuals for anti-HPV-16/18 vaccines is reached, poli-
ymakers are likely to adopt national policies for mass
accination of targeted populations.
An important ﬁrst step in implementing anti-HPV-16/18
accines in Asia should be to focus on heightening awareness
f the need for effective strategies for cervical cancer pre-
ention and the role of opportunistic vaccination among the
eneral public and primary healthcare workers. In a two-
ronged approach, a private-public partnership between
ndustry and global charity organisations on competitive
nancing will further catalyse the wider acceptance of
ervical cancer vaccination.
oi:10.1016/j.ijid.2008.05.104
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TI: Treatment Challenges
. Esposito1,∗, B. Barsic2
Institute of Pediatrics, University of Milan, Fondazione
RCCS ‘Ospedale Maggiore Policlinico, Mangiagalli e Regina
lena’, Milan, Italy
Hospital for Infectious Diseases, School of Medicine,
agreb, Croatia
evere community-acquired pneumonia (CAP) treated in
ntensive care units (ICU) represents a great therapeutic
hallenge. There is growing evidence on the importance of
typical pathogens and combined infections as causes of
evere CAP. Data from our single-center study show that
egionella and atypical pathogens are associated with over
0% of CAP. That is why combined ceftriaxone and par-
nteral azithromycin therapy became a standard treatment
n our ICU. This is congruent with a majority of contempo-
ary treatment guidelines which recognized the importance
f a combined treatment of severe CAP. Evidences on the
ole of atypical pathogens, particularly C. pneumoniae,
n the etiology of nosocomial pneumonia (NP), including
entilator-associated pneumoniae (VAP), are also emerg-
ng. These pathogens are not so well recognized as possible
athogens and considered in present treatment guidelines
f NP. Further surveillance is needed which might change
ur initial therapeutic approach in patients with NP.
In pediatric patients, Mycoplasma pneumoniae and
hlamydophila pneumoniae seem to play a more signiﬁcant
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role in causing respiratory tract infections than previously
thought. These atypical bacteria have been associated
with acute tonsillopharyngitis (AT) and, unless adequately
treated with antimicrobial therapy, it has been demon-
strated that they can cause recurrent episodes of this
disease. Moreover, it has recently been observed that the
great majority of the children with a history of severely
recurrent AT (and therefore considered eligible for elec-
tive tonsillectomy) are infected by atypical bacteria and
that tonsillectomy seems to be effective in reducing the
recurrence of both AT and acute respiratory disease in the
presence of such infections. This means that treatment with
macrolides can solve the acute illness and reduce the risk of
new recurrences in the case of M. pneumoniae or C. pneu-
moniae infections and that appropriate treatment might
postpone or abolish the need of tonsillectomy.
doi:10.1016/j.ijid.2008.05.105
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Chlamydia trachomatis: Area Under the Iceberg
I. Sziller
First Department of Obstetrics and Gynecology, Semmel-
weis University Medical School, Budapest, Hungary
In both sexes, genital Chlamydia trachomatis infection is
still the most commonly reported bacterial sexually trans-
mitted infectious disease worldwide. The prevalence is
highest in persons aged less than 25 years. In females,
up to 40% of chlamydial cervicitis might ascend to the
endometrium, and is responsible for the etiology of
endometritis and salpingitis. Late sequels of Fallopian tube
involvement include pelvic inﬂammatory disease, ectopic
pregnancy, tubal factor infertility and chronic pelvic pain.
Since the overwhelming majority of primary infections (ure-
thritis in men and cervicitis or urethritis in women) are
asymptomatic, early diagnosis should essentially rely on
annual screening of sexually active young women as well
as men at high risk sexual behavior. At present, nucleic
acid ampliﬁcation techniques (NAAT) are the most sensi-
tive tests for the detection of the pathogen in male and
female biological samples. Over the last decade, adminis-
tration of a single oral dose of 1000mg azithromycin is the
recommended treatment for uncomplicated primary geni-
tal chlamydial infection in men and women. In addition,
azithromycin was shown to be as effective as amoxicillin
or erythromycin for the eradication of C. trachomatis infec-
tion in pregnant women and this regimen resulted in less
adverse events. In a recent multicenter study in Central
and Eastern Europe, prevalence of endocervical chlamydial
infection in women aged less than 25 years was 6%, with
signiﬁcant differences of frequencies among some geograph-
ical areas. Risk factors of infection were in accordance with
those reported form other parts of Europe.
doi:10.1016/j.ijid.2008.05.106
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cne vulgaris - Old/New Treatment?
. Zelenkova
DOST Private Department of Dermatovenereology, Svidnik,
lovakia
cne vulgaris is one of the most frequent skin diseases
ffecting predominantly adolescents. The therapy depends
n the severity of the disease. Systemic antibiotics in acne
reatment have always been a controversial topic, as depre-
ated and respected at the same time. Pulse azithromycin
herapy has devoted attention of many dermatologists. Sev-
ral studies on this therapy were published so far, but
osage regimens in pulsed azithromycin therapy slightly dif-
er between studies. However, all of them present that
zithromycin has better clinical efﬁcacy and safety than
ystemic minocycline or tetracycline. At our department,
zithromycin has been administered and studied for four and
alf years now, with remarkable results. We have compared
he effect of azithromycin against quinolones and tetracy-
lines. Three groups (30 patients each) of comparable age
aged 14—18 years) and gender suffering from moderate
cne papulopostulosa (Cook’s acne severity grading scale
—6) were observed. Azithromycin was administered 500mg
rally during three subsequent days, followed by 500mg
eekly for the following six weeks. Oﬂoxacin was admin-
stered 100mg for ﬁve days, 100mg once daily following
0 days and 50mg once daily during ﬁve weeks. Doxycy-
line was administered 100mg twice daily for ﬁve days,
00mg once daily for 10 days and 50mg once daily following
ve weeks. Topical agents containing ichthamol and azelaic
cid were applied. Signiﬁcantly better results (reduction in
nﬂammatory lesions) were observed after the third treat-
ent week in the azithromycin group. The results remained
igniﬁcant even after therapy termination and at the follow-
p visit (ﬁve months after therapy termination). Also, no
dverse events were recorded in the azithromycin group.
oi:10.1016/j.ijid.2008.05.107
6.004
cute Infectious Gastroenterocolitis: Use or Not to Use
ntibiotics?
. Vukelic
University Hospital for Infectious Diseases ‘Dr Fran
ihaljevic’, Zagreb, Croatia
ravelers’ diarrhea (TD) is the leading cause of morbidity
n travelers. This lecture will primarily address pediatric TD
y discussing existing data on children as well as extrapola-
ion of appropriate adult data and will propose reasonable
herapeutic parameters for infants and children. TD is rarely
ssociated with mortality though it is responsible for signiﬁ-
ant morbidity in traveling infants and children. Untreated,
D in children may last for days or even weeks. Prevention
f TD generally includes dietary counseling and occasion-
lly the use of chemoprophylaxis. The use of antimicrobial
nd antidiarrheal agents for the treatment of TD in chil-
ren is controversial and there is still little data published
nd no ﬁrm recommendations available to guide the clin-
